Unity Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 19
- Market Cap
- $28.1M
- Introduction
Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 ...
UNITY Biotechnology to Host In-Person Ophthalmology Day
UNITY Biotechnology to host an in-person and virtual event on October 15, 2024, featuring ophthalmology KOLs and management. The event will focus on the Phase 2b ASPIRE study evaluating UBX1325 in diabetic macular edema (DME), with 24-week and 36-week data expected in Q1 and Q2 2025, respectively.
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday
UNITY Biotechnology hosts in-person and virtual Ophthalmology Day on Oct 15, 2024, in NY, featuring KOLs and management discussing the Phase 2b ASPIRE study evaluating foselutoclax (UBX1325) vs. aflibercept in DME. Expected 24-week data in Q1 2025, 36-week data in Q2 2025. Virtual attendees can access via UNITY's website.
Immortality moonshot: A quest of the rich for eternal life (and anti-ageing creams)
Billionaires invest heavily in anti-aging research, driven by personal fears of aging and death, fueling a market projected to reach $421.4 billion by 2030. Silicon Valley entrepreneurs, like Bryan Johnson, spend millions on biohacking to extend their lives, turning their bodies into 'racing cars' in a competitive quest for immortality.
© Copyright 2024. All Rights Reserved by MedPath